Back to Search Start Over

Recent advances and emerging therapies in anaplastic thyroid carcinoma [version 1; referees: 3 approved]

Authors :
Maria E. Cabanillas
Mark Zafereo
Michelle D. Williams
Renata Ferrarotto
Ramona Dadu
Neil Gross
G. Brandon Gunn
Heath Skinner
Gilbert Cote
Horiana B. Grosu
Priyanka Iyer
Naifa L. Busaidy
Author Affiliations :
<relatesTo>1</relatesTo>Department of Endocrine Neoplasia & Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA<br /><relatesTo>2</relatesTo>Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA<br /><relatesTo>3</relatesTo>Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA<br /><relatesTo>4</relatesTo>Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 515 Holcombe Blvd, Houston, TX, 77030, USA<br /><relatesTo>5</relatesTo>Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA<br /><relatesTo>6</relatesTo>Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Source :
F1000Research. 7:F1000 Faculty Rev-87
Publication Year :
2018
Publisher :
London, UK: F1000 Research Limited, 2018.

Abstract

Anaplastic thyroid cancer is a rare and aggressive thyroid cancer with an overall survival measured in months. Because of this poor prognosis and often advanced age at presentation, these patients have traditionally been treated palliatively and referred for hospice. However, recent progress using novel therapies has energized the field, and several promising clinical trials are now available for these patients. This review will highlight this progress and the potential treatments that could pave the way to improved outcomes and quality of life for patients with this disease.

Subjects

Subjects :
Review
Articles
BRAF
dabrafenib
trametinib
vemurafenib
squamous
sarcomatoid
anaplastic thyroid cancer
dedifferentiated
undifferentiated
targeted therapy
chemotherapy
NTRK

Details

ISSN :
20461402
Volume :
7
Database :
F1000Research
Journal :
F1000Research
Notes :
Editorial Note on the Review Process F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version). The referees who approved this article are: Ashok R Shaha, Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA No competing interests were disclosed. Vera Tiedje, Department of Endocrinology and Metabolism, University Hospital Essen and University Duisburg-Essen, Essen, Germany No competing interests were disclosed. Ana O Hoff, Department of Endocrinology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil No competing interests were disclosed., , [version 1; referees: 3 approved]
Publication Type :
Academic Journal
Accession number :
edsfor.10.12688.f1000research.13124.1
Document Type :
review
Full Text :
https://doi.org/10.12688/f1000research.13124.1
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details